Arvind Akshay

Arvind Akshay

Active Director Director DIN 05355266
DIN 05355266 First appointment Aug 2015 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 2 historical roles
Total affiliations 6 Since Aug 2015
Shareholding value •••• Premium profile

About Arvind Akshay

Data last updated:

Arvind Akshay is a Director at Regenix Drugs Limited (since 2022), Designated Partner at D Arvind & Associates Llp (since 2015) and Director at Daa Consulting Private Limited (since 2019), and holds 1 more current directorship. The companies operate in Healthcare, Information Technology and Business Outsourcing. The 3 current companies with reported revenue have a combined latest revenue of ₹196 Cr; the largest is Regenix Drugs Limited at ₹188 Cr (FY 2024). Earlier, Arvind Akshay was a Director at Paterson Lubricants India Private Limited (2016–2022) and Designated Partner at Rosefield Daa International Consultancy Llp (2015–2018).

DIN 05355266
Primary Designation Director
Industry Healthcare
First Appointment 05 Aug 2015
Oldest Company Age 19 yrs
Largest company Regenix Drugs Limited · ₹188 Cr (FY 2024)
Combined revenue ₹196 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Regenix Drugs Limited U24232TN2007PLC063446
Director25 Sep 20222007₹188 Cr (FY 2024)Active
Designated Partner12 Oct 20152015₹4.95 Cr (FY 2021)Active
Daa Consulting Private Limited U74140MH2019PTC327763
Director09 Jul 20192019₹2.70 Cr (FY 2025)Active
Daa Technologies Private Limited U63030TN2021PTC143277
Director05 May 20212021Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Dec 20162016₹70.8 Lakh (FY 2023)Under Process Of Striking Off
Designated Partner05 Aug 20152015Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Regenix Drugs Limited
Daa Technologies Private Limited
Daa Consulting Private Limited
D Arvind & Associates Llp
Premium access

Shareholding and investment profile for Arvind Akshay

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Arvind Akshay

Arvind Akshay currently holds 4 directorships: Regenix Drugs Limited (Director, since 25 Sep 2022, revenue ₹188 Cr (FY 2024)); D Arvind & Associates Llp (Designated Partner, since 12 Oct 2015, revenue ₹4.95 Cr (FY 2021)); Daa Consulting Private Limited (Director, since 09 Jul 2019, revenue ₹2.70 Cr (FY 2025)); Daa Technologies Private Limited (Director, since 05 May 2021).

Arvind Akshay was first appointed on 05 Aug 2015 as Designated Partner at Rosefield Daa International Consultancy Llp. The most recent appointment on record is 25 Sep 2022 at Regenix Drugs Limited.

The 3 current companies of Arvind Akshay that report revenue have a combined latest revenue of ₹196 Cr: Regenix Drugs Limited ₹188 Cr (FY 2024); D Arvind & Associates Llp ₹4.95 Cr (FY 2021); Daa Consulting Private Limited ₹2.70 Cr (FY 2025).

Arvind Akshay held 2 earlier board appointments: Paterson Lubricants India Private Limited (Director, 26 Dec 2016 to 30 Sep 2022); Rosefield Daa International Consultancy Llp (Designated Partner, 05 Aug 2015 to 19 Feb 2018).

The current boards of Arvind Akshay's companies include Ayyamperumal (Regenix Drugs Limited), Balaji Ramamurthy (Regenix Drugs Limited), Govindarajan Venkatakrishna (Regenix Drugs Limited), Guhan Ramamurthy (Regenix Drugs Limited), Gunasekaran Raju (Regenix Drugs Limited), Krishanamoorthy Nirosha (Regenix Drugs Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available